Browse by author
Lookup NU author(s): Dr Daniel ErskineORCiD
This is the authors' accepted manuscript of an article that has been published in its final definitive form by Wiley-Blackwell, 2019.
For re-use rights please refer to the publisher's terms and conditions.
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease and is estimated to affect approximately 1‐4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease‐modifying therapies for Parkinson's disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson's disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non‐invasive means is a pressing issue in the field. Since the discovery of α‐synuclein as a protein linked to a familial form of Parkinson's disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson's disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson's disease biomarker discovery with a focus on α‐synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α‐synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions.
Author(s): Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, El-Agnaf OMA
Publication type: Article
Publication status: Published
Journal: Journal of Neurochemistry
Print publication date: 01/09/2019
Online publication date: 02/07/2019
Acceptance date: 27/06/2019
Date deposited: 24/07/2019
ISSN (print): 0022-3042
ISSN (electronic): 1471-4159
PubMed id: 31265130
Altmetrics provided by Altmetric